Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A New CEO And Perhaps A New Era At Shire: An Interview With Flemming Ornskov

Executive Summary

Making his public debut as Shire CEO at the World Orphan Drug Congress, Flemming Ornskov talked with “The Pink Sheet” about his four-month transition period as Angus Russell’s designated successor, how his background in pediatrics may guide business development, and whether he plans to revise the specialty pharma’s business model or hew to his predecessor’s course.

You may also be interested in...



Deals Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?

Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.

Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment

Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.

Shire Expands Rare Disease R&D With Boston Tie-Up

Shire is teaming up with Children’s Hospital Boston to find therapies for rare pediatric diseases in a three-year collaboration that will capitalize on the strengths of both partners.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS055255

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel